- Home
- GNW vs MLTX Comparison
GNW vs MLTX Comparison
Compare GNW & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNW
- MLTX
- Stock Information
- Founded
- GNW 1871
- MLTX 2021
- Country
- GNW United States
- MLTX Switzerland
- Employees
- GNW N/A
- MLTX N/A
- Industry
- GNW Life Insurance
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- GNW Finance
- MLTX Health Care
- Exchange
- GNW Nasdaq
- MLTX Nasdaq
- Market Cap
- GNW 2.9B
- MLTX 2.8B
- IPO Year
- GNW 2004
- MLTX N/A
- Fundamental
- Price
- GNW $7.93
- MLTX $47.55
- Analyst Decision
- GNW Buy
- MLTX Strong Buy
- Analyst Count
- GNW 1
- MLTX 8
- Target Price
- GNW $9.00
- MLTX $77.71
- AVG Volume (30 Days)
- GNW 7.7M
- MLTX 752.7K
- Earning Date
- GNW 07-30-2025
- MLTX 08-06-2025
- Dividend Yield
- GNW N/A
- MLTX N/A
- EPS Growth
- GNW 141.92
- MLTX N/A
- EPS
- GNW 0.49
- MLTX N/A
- Revenue
- GNW $7,217,000,000.00
- MLTX N/A
- Revenue This Year
- GNW N/A
- MLTX $103.42
- Revenue Next Year
- GNW N/A
- MLTX N/A
- P/E Ratio
- GNW $14.93
- MLTX N/A
- Revenue Growth
- GNW N/A
- MLTX N/A
- 52 Week Low
- GNW $5.95
- MLTX $31.42
- 52 Week High
- GNW $8.00
- MLTX $58.26
- Technical
- Relative Strength Index (RSI)
- GNW 64.14
- MLTX 60.27
- Support Level
- GNW $7.71
- MLTX $42.22
- Resistance Level
- GNW $7.88
- MLTX $48.72
- Average True Range (ATR)
- GNW 0.23
- MLTX 1.60
- MACD
- GNW 0.05
- MLTX 0.09
- Stochastic Oscillator
- GNW 89.21
- MLTX 70.15
About GNW Genworth Financial Inc
Genworth Financial Inc is a diversified insurance holding company that provides various mortgage and life insurance products. The company has three main operating business segments: Enact, Life and Annuities segment and Long-Term Care Insurance. The company's product portfolio includes various financial products such as traditional life insurance, mortgage insurance, fixed annuities, and variable annuities. Majority of the revenue is generated by the Enact segment. The company earns maximum of its revenue in the United States.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.